BibTex RIS Kaynak Göster

Multiple Sklerozlu Hastalarda Hastalık Modifiye Edici İlaç Tedavisine Uyumu Etkileyen Faktörler

Yıl 2018, Cilt: 11 Sayı: 2, 164 - 172, 01.05.2018

Öz

Giriş: Multiple Sklerozlu hastalarda ilaç tedavisine uyum; tedavi etkinliğinin artırılması, hastanın engellilik oranının azaltılması, atakların önlenmesi ve yaşam kalitesinin artırılması için önemlidir. Amaç: Araştırma MS hastalarının hastalık modifiye edici ilaç tedavisine uyumu etkileyen faktörleri belirlemek amacıyla yapılmıştır. Yöntem: Tanımlayıcı türdeki bu araştırma Ege Üniversitesi Tıp Fakültesi Hastanesi Nöroloji Anabilim Dalı MS polikliniğinde Temmuz 2016-Şubat 2017 tarihleri arasında, araştırma sınırlıklarına uyan ve araştırmaya katılmayı kabul eden 198 MS hastası ile yürütülmüştür. Araştırmanın verileri; araştırmacı tarafından hazırlanan Birey Tanıtım Formu, Multiple Skleroz Tedaviye Uyum Anketi, Yorgunluk Şiddeti Ölçeği, Öz Etkililik/Yeterlik Ölçeği ve Başa Çıkma Stilleri Ölçeği Kısa Formu kullanılarak toplanmıştır. Bulgular: Hastaların %59.6’sı ilaç tedavisine uyumlu, %40.4’ü ilaç tedavisine uyumsuz olarak bulunmuştur. Avonex ilaç tedavisine uyum en yüksek olarak belirlenmiş, uyumsuz hastaların ilaç tedavilerini en çok atlama veya unutma nedeni “Hafıza (bellek) sorunları” olarak saptanmıştır. Hastaların sosyo-demografik ve hastalığa ilişkin özellikleri ile ilaç tedavisine uyum arasında anlamlı bir ilişki saptanmıştır (p<0.05). Hastaların başa çıkma tutumları, yorgunluk ve öz etkililik/yeterlik düzeyi ile ilaç tedavisine uyum arasında anlamlı bir fark bulunmamıştır (p>0.05). Sonuç: MS hastalarının ilaç tedavisine uyumu düşük olarak bulunmuş ve bunu etkileyen bazı sosyal, fiziksel ve bilişsel nedenlerin olduğu saptanmıştır.

Kaynakça

  • AL-Sabbagh, A., Bennett, R., Kozma, C., Dickson, M., Meletiche, D. (2008). Medication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care database. Journal of Neurology, 255 (Suppl 2), S79.
  • Albrecht, G., Hoogstraten, J. (1998). Satisfaction as a determinant of compliance. Community Dentistry And Oral Epidemiology, 26 (2), 139-146.
  • Armutlu, K., Korkmaz, N.C., Keser, I., Sumbuloglu, V., Akbiyik, D.I., Guney, Z., et. al. (2007). The validity and reliability of the fatigue severity scale in Turkish multiple sclerosis patients. International Journal of Rehabilitation Research, 30 (1), 81-85.
  • Bacanlı, H., Sürücü, M., İlhan, T. (2013). Başa çıkma stilleri ölçeği kısa formunun (BÇSÖ-KF) psikometrik özelliklerinin incelenmesi: geçerlik ve güvenirlik çalışması. Kuram Ve Uygulamada Eğitim Bilimler, 13 (1), 81-96.
  • Bandura, A. (1977). Self-efficacy: toward a unifying theory of behavioral change. Psychological Review, 84 (2), 191–215.
  • Barnwell, A.M., Kavanagh, D.J. (1997). Prediction of psychological adjustment to multiple sclerosis. Social Science & Medicine, 45 (3), 411–418.
  • Beer, K., Müller, M., Hew-Winzeler, A.M., Bont, A., Maire, P., You, X., et. al. (2011). The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study. BioMed Central Neurology, 11, 144.
  • Bishop, M., Frain, M. (2011). The multiple sclerosis self-management scale: revision and psychometric analysis. Rehabilitation Psychology, 56 (2), 150–159.
  • Bruce, J.M., Hancock, L.M., Arnett, P., Lynch, S. (2010). Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. The Journal of Behavioral Medicine, 33 (3), 219-227.
  • Carver, C.S. (1997). You want to measure coping but your protocol’s too long: consider the brief COPE. International Journal of Behavioral Medicine, 4 (1), 92-100.
  • Chrystyn, H., Small, M., Milligan, G., Higgins, V., Gil, E.G., Estruch, J. (2014). Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPD. Respiratory Medicine Journal, 108 (2), 358-365.
  • Conway, D., Cohen, J.A. (2010). Emerging oral therapies in multiple sclerosis. Current Neurology And Neuroscience Reports, 10 (5), 381–388.
  • Cooper, C., Carpenter, I., Katona, C., Schroll, M., Wagner, C., Fialova, D., et al. (2005). The AdHOC study of older adults' adherence to medication in 11 countries. The American Journal of Geriatric Psychiatry, 13 (12), 1067-1076.
  • Coyle, P.K., Cohen, B.A., Leist, T., Markowitz, C., Oleen-Burkey, M., Schwartz, M., et. al. (2014). Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes. BioMedNeurology, 13, 14- 49.
  • De Geest, S., Sabaté, E. (2003). Adherence to long-term therapies: evidence for action. European Journal of Cardiovascular Nursing, 2 (4), 323.
  • Dibrivnaia, K.A., Enikolopova, E.V., Zubkova, Iu. V., Boĭko, A.N. (2013). Characteristics of coping strategies in patients with multiple sclerosis (review). Zhurnal Nevrologii İ Psikhiatrii İmeni, 113 (2 Pt 2), 48-52.
  • Frazier, P.A., Davis-Ali, S.H., Dahl, K.E. (1994). Correlates of noncompliance among renal transplant recipients. Clinical Transplant, 8 (6), 550-557.
  • Gözüm, S., Aksayan, S. (1999). Öz etkililik-yeterlik ölçeğinin Türkçe formunun güvenirlik ve geçerliliği. Atatürk Üniversitesi Hemşirelik YüksekokuluDergisi, 1, 21-34.
  • Gözüm, S., Aksayan S. (2003). Kültürlerarası ölçek uyarlaması için rehber II: psikometrik özellikler ve kültürlerarası karşılaşma. Hemşirelikte Araştırma Geliştirme Dergisi, 1, 3-14.
  • Hambleton, R.K. (1994). Guidelines for adapting educational and psychological tests: a progress report. European Journal of Psychological Assessment, 10 (3), 229-244.
  • Hirji, I., Gupta, S., Goren, A., Chirovsky, D.R., Moadel, A.B., Olavarria, E. (2013). Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective. Health And Quality of Life Outcomes, 8 (11), 167.
  • Johansson, S., Ytterberg, C., Gottberg, K., Widén Holmqvist, L., Von Koch, L. (2008). Use of health services in people with multiple sclerosis with and without fatigue. Multiple Sclerosis Journal, 15 (1), 88–95.
  • Kavanagh, D.J., Gooley, S., Wilson, P.H. (1993). Prediction of adherence and control in diabetes. Journal Of Behavioral Medicine, 16 (5), 509-522.
  • Köşkderelioğlu, A., Gedizlioğlu, M., Ortan, P., Öcek Ö. (2015). Multiple skleroz hastalarında immunmodulatör tedaviye uyumun değerlendirilmesi. Archives of Neuropsychiatry, 52, 376-379.
  • Krueger, K.P., Berger, B.A., Felkey, B. (2005). Medication adherence and persistence: a comprehensive review. Advances in Therapy Journals, 22 (4), 313-356.
  • Krupp, L.B., LaRocca, N.G., Muir-Nash, J., Steinberg, A.D. (1989). The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Archives of Neurology, 46 (10), 1121-1123.
  • Lode, K., Larsen, J.P., Bru, E., Klevan, G., Myhr, K.M., Nyland, H. (2007). Patient information and coping styles in multiple sclerosis. Multiple Sclerosis Journal, 13 (6), 792-799.
  • Maan, C.G., Munnawar Hussain, M.S., Heramani, N., Lenin R.K. (2015). Factors affecting non-compliance among psychiatric patients in the regional institute of medical sciences. International Organization of Scientific Research Journal of Pharmacy, 5 (1), 01-07.

Factors That Affect Adherence of Disease-Modifying Therapy in Patients with Multiple Sclerosis

Yıl 2018, Cilt: 11 Sayı: 2, 164 - 172, 01.05.2018

Öz

Objective: This study was conducted to investigate factors that influence adherence of disease-modifying therapy in Multiple Sclerosis
patients. Methods: This descriptive study was conducted with 198 MS patients who meeting the inclusion criteria and accepting to
participate in Ege University Faculty of Medicine, Department of Neurology, MS clinic between July 2016 and February 2017. Data were
collected by using Individual Identification Form prepared by the researcher that including the sociodemographic characteristics, The
Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ), Fatigue Severity Scale, The Self Efficacy Scale and The Brief COPE.
Results: Patients were adherent to therapy (59.6%) and 40.4% of patients were nonadherent to therapy. Avonex were significantly more
adherent then other treatments and “Memory problems” have been found the most reason of missing or forgetting medication treatment in
nonadherent patients. There was significant difference between medication adherence and some socio-demographic characteristics and
characteristics of the disease. There was no significant difference between coping attitudes, fatigue and self efficacy level and medication
adherence. Conclusion: As a result, patients' adherence with medication treatment was found low and there were some social, physical and
cognitive reasons affecting it.

Kaynakça

  • AL-Sabbagh, A., Bennett, R., Kozma, C., Dickson, M., Meletiche, D. (2008). Medication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care database. Journal of Neurology, 255 (Suppl 2), S79.
  • Albrecht, G., Hoogstraten, J. (1998). Satisfaction as a determinant of compliance. Community Dentistry And Oral Epidemiology, 26 (2), 139-146.
  • Armutlu, K., Korkmaz, N.C., Keser, I., Sumbuloglu, V., Akbiyik, D.I., Guney, Z., et. al. (2007). The validity and reliability of the fatigue severity scale in Turkish multiple sclerosis patients. International Journal of Rehabilitation Research, 30 (1), 81-85.
  • Bacanlı, H., Sürücü, M., İlhan, T. (2013). Başa çıkma stilleri ölçeği kısa formunun (BÇSÖ-KF) psikometrik özelliklerinin incelenmesi: geçerlik ve güvenirlik çalışması. Kuram Ve Uygulamada Eğitim Bilimler, 13 (1), 81-96.
  • Bandura, A. (1977). Self-efficacy: toward a unifying theory of behavioral change. Psychological Review, 84 (2), 191–215.
  • Barnwell, A.M., Kavanagh, D.J. (1997). Prediction of psychological adjustment to multiple sclerosis. Social Science & Medicine, 45 (3), 411–418.
  • Beer, K., Müller, M., Hew-Winzeler, A.M., Bont, A., Maire, P., You, X., et. al. (2011). The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study. BioMed Central Neurology, 11, 144.
  • Bishop, M., Frain, M. (2011). The multiple sclerosis self-management scale: revision and psychometric analysis. Rehabilitation Psychology, 56 (2), 150–159.
  • Bruce, J.M., Hancock, L.M., Arnett, P., Lynch, S. (2010). Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. The Journal of Behavioral Medicine, 33 (3), 219-227.
  • Carver, C.S. (1997). You want to measure coping but your protocol’s too long: consider the brief COPE. International Journal of Behavioral Medicine, 4 (1), 92-100.
  • Chrystyn, H., Small, M., Milligan, G., Higgins, V., Gil, E.G., Estruch, J. (2014). Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPD. Respiratory Medicine Journal, 108 (2), 358-365.
  • Conway, D., Cohen, J.A. (2010). Emerging oral therapies in multiple sclerosis. Current Neurology And Neuroscience Reports, 10 (5), 381–388.
  • Cooper, C., Carpenter, I., Katona, C., Schroll, M., Wagner, C., Fialova, D., et al. (2005). The AdHOC study of older adults' adherence to medication in 11 countries. The American Journal of Geriatric Psychiatry, 13 (12), 1067-1076.
  • Coyle, P.K., Cohen, B.A., Leist, T., Markowitz, C., Oleen-Burkey, M., Schwartz, M., et. al. (2014). Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes. BioMedNeurology, 13, 14- 49.
  • De Geest, S., Sabaté, E. (2003). Adherence to long-term therapies: evidence for action. European Journal of Cardiovascular Nursing, 2 (4), 323.
  • Dibrivnaia, K.A., Enikolopova, E.V., Zubkova, Iu. V., Boĭko, A.N. (2013). Characteristics of coping strategies in patients with multiple sclerosis (review). Zhurnal Nevrologii İ Psikhiatrii İmeni, 113 (2 Pt 2), 48-52.
  • Frazier, P.A., Davis-Ali, S.H., Dahl, K.E. (1994). Correlates of noncompliance among renal transplant recipients. Clinical Transplant, 8 (6), 550-557.
  • Gözüm, S., Aksayan, S. (1999). Öz etkililik-yeterlik ölçeğinin Türkçe formunun güvenirlik ve geçerliliği. Atatürk Üniversitesi Hemşirelik YüksekokuluDergisi, 1, 21-34.
  • Gözüm, S., Aksayan S. (2003). Kültürlerarası ölçek uyarlaması için rehber II: psikometrik özellikler ve kültürlerarası karşılaşma. Hemşirelikte Araştırma Geliştirme Dergisi, 1, 3-14.
  • Hambleton, R.K. (1994). Guidelines for adapting educational and psychological tests: a progress report. European Journal of Psychological Assessment, 10 (3), 229-244.
  • Hirji, I., Gupta, S., Goren, A., Chirovsky, D.R., Moadel, A.B., Olavarria, E. (2013). Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective. Health And Quality of Life Outcomes, 8 (11), 167.
  • Johansson, S., Ytterberg, C., Gottberg, K., Widén Holmqvist, L., Von Koch, L. (2008). Use of health services in people with multiple sclerosis with and without fatigue. Multiple Sclerosis Journal, 15 (1), 88–95.
  • Kavanagh, D.J., Gooley, S., Wilson, P.H. (1993). Prediction of adherence and control in diabetes. Journal Of Behavioral Medicine, 16 (5), 509-522.
  • Köşkderelioğlu, A., Gedizlioğlu, M., Ortan, P., Öcek Ö. (2015). Multiple skleroz hastalarında immunmodulatör tedaviye uyumun değerlendirilmesi. Archives of Neuropsychiatry, 52, 376-379.
  • Krueger, K.P., Berger, B.A., Felkey, B. (2005). Medication adherence and persistence: a comprehensive review. Advances in Therapy Journals, 22 (4), 313-356.
  • Krupp, L.B., LaRocca, N.G., Muir-Nash, J., Steinberg, A.D. (1989). The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Archives of Neurology, 46 (10), 1121-1123.
  • Lode, K., Larsen, J.P., Bru, E., Klevan, G., Myhr, K.M., Nyland, H. (2007). Patient information and coping styles in multiple sclerosis. Multiple Sclerosis Journal, 13 (6), 792-799.
  • Maan, C.G., Munnawar Hussain, M.S., Heramani, N., Lenin R.K. (2015). Factors affecting non-compliance among psychiatric patients in the regional institute of medical sciences. International Organization of Scientific Research Journal of Pharmacy, 5 (1), 01-07.
Toplam 28 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Research Article
Yazarlar

Öznur Erbay Bu kişi benim

Öznur Usta Yeşilbalkan Bu kişi benim

Ayşenur Yüceyar Bu kişi benim

Yayımlanma Tarihi 1 Mayıs 2018
Yayımlandığı Sayı Yıl 2018 Cilt: 11 Sayı: 2

Kaynak Göster

APA Erbay, Ö., Yeşilbalkan, Ö. U., & Yüceyar, A. (2018). Multiple Sklerozlu Hastalarda Hastalık Modifiye Edici İlaç Tedavisine Uyumu Etkileyen Faktörler. Dokuz Eylül Üniversitesi Hemşirelik Fakültesi Elektronik Dergisi, 11(2), 164-172.

Dokuz Eylül Üniversitesi Hemşirelik Fakültesi Elektronik Dergisi ULAKBİM Türk Tıp Dizini, Türk Medline, Türkiye Atıf Dizini, Şubat 2021 tarihinden beri EBSCO Host ve 26 Ekim 2021 tarihinden itibaren DOAJ ve 18 Ocak 2022 tarihinden beri Index Copernicus tarafından indekslenmektedir.

349202.svg        14839           wp-logo.png          ici2.png           Scopus_logo.svg 

       

      

Creative Commons License
Dokuz Eylül Üniversitesi Hemşirelik Fakültesi Elektronik Dergisi Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License ile lisanslanmıştır.